DRUG DELIVERY – Tunable Half-Life Extension Based on Recombinant Albumin – Tailoring Pharmaceuticals to Specific Medical Needs
Mark Perkins, PhD, reviews the development of a tunable half-life technology to serve as a flexible drug delivery platform designed to enable manufacturers to tailor protein or peptide half-lives to specific medical needs.
Dr. Rod Ray, CEO and Chairman at Bend Research, discusses his company’s approach to difficult drug delivery challenges and the core technologies offered by his company.
Dr. Jean-Luc Herbeaux, the Head of the Health Care Business Line of Evonik, discusses the rationale and success of his company’s latest acquisition.
Contributor Cindy H. Dubin interviewed leading players in the prefilled syringe market to find out about their offerings and how they are addressing pharma’s needs for safety, ease of use, cost, and product differentiation.
James D. Ingebrand, VP & General manager of 3M DDS, discusses his priorities for the years ahead and recent developments in 3M’s technologies.
DRUG DEVELOPMENT – Design & Development of Atorvastatin Orally Disintegrating Tablets & Their Evaluation by Electronic Tongue
Rakesh Kumar Bhasin, MPharm, and Pradip Kumar Ghosh, PhD, design and develop a good taste-masked atorvastatin ODT that matched the in vitro release profile of Lipitor.
Robert Gwozdz, MPharm, presents an overview of polymers used in the more exotic and technically challenging dosage forms involving MR as well as those used for enhancing the dissolution and bioavailability of poorly soluble APIs.
Mr. Ben Moga, President of Ratio, Inc., talks about his company’s focus on self-injection in a homecare setting and how Ratio is pitting the patch injector against conventional autoinjectors in what is projected to be a $15.8 billion injectable drug delivery device market.
FORMULATION DEVELOPMENT – In Vitro Diffusion Studies in Transdermal Research: A Synthetic Membrane Model in Place of Human Skin
Vivek Joshi, PhD, David Brewster, and Peter Colonero present data on the applicability of a synthetic membrane (Strat-MTM) for in vitro transdermal diffusion studies in place of human or animal skin as a model.
Suniket Fulzele, PhD; Derek Moe, PhD; and Ehab Hamed, PhD; review the lyophilized wafer technology, specifically Lyoc, that offered the world’s first ODT, ODA Lyoc (sodium saccharinate and flamenol) in 1968.
EXCLUSIVE ONLINE CONTENT
Radius Health, Inc. recently announced it has entered into definitive agreements with Endo Ventures Limited, a subsidiary of Endo International plc to register, commercialize, and distribute abaloparatide on an exclusive basis in….
Vectura Group plc recently announced its partner Hikma Pharmaceuticals has launched its generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder)….
Gattefossé is investing 30 million euros in its industrial operations and announced the construction of a brand new manufacturing plant in Lufkin, TX. This asset will produce lipid-based….
BD (Becton, Dickinson and Company) recently announced publication of the results from a 52-subject human clinical trial with the BD Libertas Wearable Injector…..
Vectura Group plc recently announced it has signed a global outlicense and development agreement with Kinaset Therapeutics Inc. for the development and commercialization of….